These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17505265)

  • 1. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
    Moschos SJ; Odoux C; Land SR; Agarwala S; Friedland D; Volker KM; Sidor C; Wong M; Kirkwood JM
    Melanoma Res; 2007 Jun; 17(3):193-200. PubMed ID: 17505265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
    Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
    Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
    Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
    Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
    Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
    Solti M; Berd D; Mastrangelo MJ; Sato T
    Melanoma Res; 2007 Aug; 17(4):225-31. PubMed ID: 17625452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
    J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
    Guenterberg KD; Grignol VP; Relekar KV; Varker KA; Chen HX; Kendra KL; Olencki TE; Carson WE
    Am J Clin Oncol; 2011 Feb; 34(1):87-91. PubMed ID: 20458209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
    Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
    Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS
    Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
    Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
    Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
    Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
    Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.